Wealthcare Advisory Partners LLC Increases Stock Position in Danaher Co. (NYSE:DHR)

Wealthcare Advisory Partners LLC raised its holdings in shares of Danaher Co. (NYSE:DHR) by 1.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 7,787 shares of the conglomerate’s stock after purchasing an additional 100 shares during the period. Wealthcare Advisory Partners LLC’s holdings in Danaher were worth $1,787,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of DHR. Benjamin Edwards Inc. raised its position in Danaher by 1.8% in the second quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock worth $538,000 after acquiring an additional 38 shares during the period. Wedge Capital Management L L P NC increased its stake in shares of Danaher by 3.2% in the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after purchasing an additional 38 shares in the last quarter. Certified Advisory Corp raised its holdings in Danaher by 4.5% in the 2nd quarter. Certified Advisory Corp now owns 926 shares of the conglomerate’s stock worth $231,000 after purchasing an additional 40 shares during the period. Meridian Financial Partners LLC lifted its position in Danaher by 4.4% during the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock valued at $266,000 after purchasing an additional 40 shares in the last quarter. Finally, Kovack Advisors Inc. grew its holdings in Danaher by 3.4% during the third quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock valued at $346,000 after purchasing an additional 41 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE:DHR opened at $238.41 on Friday. The firm has a market capitalization of $172.20 billion, a PE ratio of 45.50, a PEG ratio of 4.23 and a beta of 0.83. The stock’s fifty day moving average is $234.85 and its 200 day moving average is $253.32. Danaher Co. has a fifty-two week low of $222.53 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.02 earnings per share. On average, sell-side analysts anticipate that Danaher Co. will post 7.49 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. Danaher’s dividend payout ratio is 20.61%.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of analyst reports. Robert W. Baird lowered their price objective on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. KeyCorp upped their price target on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Barclays decreased their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. UBS Group dropped their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Finally, Stephens reissued an “overweight” rating and set a $315.00 price target on shares of Danaher in a report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $286.80.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.